APLS — Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc (APLS) is a biotechnology company listed on NASDAQ. It is led by Cedric Francois M.D., Ph.D., based in 100 Fifth Avenue, Waltham, MA, United States, 02451, with about 705 employees. Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Latest reported APLS revenue for 2025-09-30 was $458.6M. Net income was $81.3M. Revenue was up 156.9% from 2025-06-30 to 2025-09-30. APLS currently screens at market cap $2.29B.

Use this APLS page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the APLS quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the APLS SEC filings page. Lician reads the product cache first so this HTML stays unique to Apellis Pharmaceuticals Inc even when a live quote feed is slow.